Reply to the Editor  by Murthy, Sudish C.
I congratulate the authors again on
a most thought-provoking study. I look
forward to their feedback about these con-
siderations.
John G. T. Augoustides, MD, FASE
Department of Anesthesiology and Critical Care
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
Financial support: Department of Anesthesiology
and Critical Care, Hospital of the University of
Pennsylvania.
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Prosthesis–patient mismatch
after mitral valve replacement:
Back to reality
To the Editor:
We read with interest the article of Totaro
and Argano.1 We have, however, several
concerns with regard to the validity of the
results and conclusions presented in this
article. First, the title of the article, ‘‘Pa-
tient–Prosthesis Mismatch after Mitral
Valve Replacement: Myth or Reality?’’ is
inappropriate. Mitral prosthesis–patient
mismatch (PPM) is equivalent to a residual
mitral stenosis, related to the fact that most
prosthetic valves have a hemodynamic per-
formance, and thus a valve effective orifice
area (EOA), that is inferior to that of the nor-
mal native valve. Thus concluding that PPM
is a myth would be equivalent to saying that
mitral stenosis (or aortic stenosis for aortic
PPM) does not exist, and that this is a benign
phenomenon, which is of course not the
case. In this regard, several studies have
demonstrated that PPM is a frequent hemo-
dynamic phenomenon after mitral or aortic
valve replacement.2-5 The important ques-
tion is rather to determine the impact of
PPM on the hemodynamic, functional, and
clinical outcomes, and at which degree of
severity and in which categories of patients
this impact of PPM becomes statistically
significant and clinically relevant. Unfortu-
nately, the data provided by Totaro and
Argano1 do not permit an answer to these
important questions.
There are serious concerns about the val-
idity of the Doppler echocardiographic data,
and especially of those of the valve EOA.
This is a crucial aspect, because the identifi-
cation and quantification of PPM are based
on these data. First, it is intriguing to see
that the EOAs measured in vivo by Doppler
echocardiography, especially for the 25- and
27-mm valves, were larger than the EOAs
measured in vitro by the manufacturer. A re-
cent study has indeed demonstrated that, as
opposed to the observation in this study, the
in vitro EOAs provided by the manufacturer
grossly overestimate the in vivo EOAs and
are thus not valid for prediction of PPM.6
Totaro and Argano also used the label pros-
thesis size as a surrogate for PPM, whereas
previous studies have shown that this
parameter is not valid for identification of
PPM and prediction of its hemodynamic
and clinical consequences.3,6,7
Moreover, the huge variability in the
EOA measurements for a given prosthesis
size (from 1.0 to 4.9 cm2 for the 29-mm pros-
theses!), the complete absence of correlation
between the EOA and the transprosthetic gra-
dient, and the recording of high transpros-
thetic gradients (.15 mm Hg) in several
patients despite the calculation of large
EOAs and indexed EOAs (see Figure 3 of
the article1) further support the concerns
regarding the validity of the EOA measure-
ments and thus the identification of PPM.
The presence of gradients greater than 15
mm Hg in the mitral position definitely
cannot be considered as ‘‘favorable hemody-
namics,’’ as concluded by Totaro and
Argano.1 In fine, these observations suggest
that a large proportion of the patients in-
cluded in this series were misclassified with
respect to the presence or absence of PPM.
Totaro and Argano only measured the
valve hemodynamics and systolic pulmo-
nary arterial pressure at predischarge exam-
ination or at 30 days. It is well known that
the measurements of valve EOA, transvalv-
ular gradients, and pulmonary pressure in
the early postoperative period are often
unreliable because of the poor acoustic win-
dow, hyperdynamic state, or flow accelera-
tion in the left ventricular outflow tract.
Letters to the EditorReply to the Editor:
We appreciate the comments provided by Dr
Augoustides in regard to our recent article
‘‘Ventilatory Dependency After Cardiovas-
cular Surgery.’’ Our article attempts to de-
fine the risks for ventilator dependency and
determine the outcomes of patients who de-
velop this problem after their index cardio-
vascular surgery. Two inquiries were made
(as points [a] and [c] are closely related).
We were surprised ourselves to find that
there has been a continuing trend toward
a lower prevalence of ventilator dependency
at our institute. A declining trend was noted
in previous studies from our institute pub-
lished several years before. That this trend
has continued through the current study
has both thrilled and perplexed us. It was im-
possible for us to determine which quantifi-
able variables might be responsible for this
trend because of a variety of confounding
factors, not the least of which is time itself.
What is even more interesting is that this
phenomenon has occurred in the setting of
increasing complexity and acuity of illness.
It is our suspicion that several coincident
changes might be responsible. There has
been a steady improvement in myocardial464 The Journal of Thoracic and Cardioprotection over the years and a progressive
increase of intraoperative echocardiography
use; these factors likely promote more rapid
myocardial recovery. Less narcotics are be-
ing given intraoperatively, and this may fa-
cilitate earlier separation from mechanical
ventilatory support. In addition, there has
been a noticeable increase in intensivist
staffing, such that there is seemingly more
planning and continuity of care in the inten-
sive care unit, which again, might favorably
affect weaning.
Second, aprotinin is used sparingly at
our institution (in ,1% of patients). This
is, in part, secondary to cost, but also for
concerns regarding thrombotic complica-
tion and renal dysfunction, all without
clearly demonstrable benefit. There are 2
populations for whom we do use aprotinin
on more occasions: patients with ventricu-
lar-assist devices and patients undergoing
a second cardiac transplant. These groups
were excluded from our study.
Sudish C. Murthy, MD, PhD
Thoracic and Cardiovascular Surgery
The Cleveland Clinic
Cleveland, Ohio
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